Thursday, January 09, 2020 9:57:58 PM
Phio Pharmaceuticals Corp. shares have an average trading volume of 1.19M shares.
Shares outstanding 36,818,956
During the last week volume has been rising sharply and today it really took off, almost half the entire share count traded.
01/09/20 PHIO 0.2535 (previous close 0.1835) Change + 0.07 Vol: 15,588,541 + 12.8%
Phio Pharmaceuticals Corporation 2019 Special Meeting of Stockholders, scheduled for December 12, 2019, was rescheduled for 9:00 a.m. (Eastern Time) at the Company's executive offices on January 10, 2020 (tomorrow). A possible reverse split of no less than 2:1 or more than 70:1 could be considered, or other means to prevent the company from being delisted. They may make an announcement during the meeting.
Since that time the company announced that it will present at Biotech Showcase™ 2020 on Monday, January 13, 2020.
It could be that instead of doing a reverse split, it will be forming a joint venture with another company, and this could bring its stock price up to compliance. They had said that they would be talking with the NASDAQ about how they would come into compliance.
The straight up move in the stock price and volume over the last several days, especially with half of ALL THE SHARES trading today, strongly suggests that insiders are taking advantage of inside information.
Tomorrow may be an explosive day.
PHIO warrants: PHIOW expire 12/21/2021
Each warrant now has an exercise price of $1.44 per warrant
PHIOW 0.018 Change -0.0125 Vol: 100
As you can see, the warrants have few trades, few bid/ask, but if we get a joint venture, our price could take off, and if a person puts in a high enough bid, but well under the price of the stock itself, they might get a fair amount of warrants, and at a good price.
Recent PHIO News
- Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells • GlobeNewswire Inc. • 04/22/2024 05:10:09 PM
- Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID) • GlobeNewswire Inc. • 04/16/2024 11:30:00 AM
- Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT) • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- National Spotlight Features Phio’s Innovative RNAi Technology Platform • GlobeNewswire Inc. • 04/03/2024 11:30:00 AM
- Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update • GlobeNewswire Inc. • 04/02/2024 11:30:00 AM
- Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies • GlobeNewswire Inc. • 03/21/2024 11:30:00 AM
- Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research • GlobeNewswire Inc. • 03/13/2024 06:00:25 PM
- Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders • GlobeNewswire Inc. • 03/06/2024 03:30:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 12:03:51 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 03:30:10 PM
- Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies • GlobeNewswire Inc. • 01/31/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 10:00:16 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/28/2023 02:13:20 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/28/2023 05:15:20 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 12/19/2023 09:52:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/08/2023 10:00:32 PM
- Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds • GlobeNewswire Inc. • 12/07/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:40:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:31:07 PM
- Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/09/2023 09:30:20 PM
- Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas • GlobeNewswire Inc. • 11/09/2023 12:30:00 PM
- Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control • GlobeNewswire Inc. • 11/03/2023 04:00:00 PM
- Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) • GlobeNewswire Inc. • 10/12/2023 03:00:00 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM